Incyte
Developer of Jakafi, Opzelura, and targeted hematology, oncology, and immune-disease medicines.
$124.37
After-hours close−0.04 (−0.03%)
At close$124.41(−2.61%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | −$2.83 | — | — |
| Jul 2026 | $2.15 | $3.09 | +43.7% |
| Apr 2026 | $1.38 | $1.81 | +31.2% |
| Feb 2026 | $1.90 | $1.80 | −5.3% |
| Oct 2025 | $1.66 | $2.26 | +36.1% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Jul 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Feb 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Oct 27, 2026 | −$2.83 | — | — | $1.47B | — | — |
| Jul 28, 2026 | $2.15 | $3.09 | +43.7% | $1.50B | $1.67B | +11.3% |
| Apr 28, 2026 | $1.38 | $1.81 | +31.2% | $1.22B | $1.27B | +4.7% |
| Feb 10, 2026 | $1.90 | $1.80 | −5.3% | $1.35B | $1.51B | +11.2% |
| Oct 28, 2025 | $1.66 | $2.26 | +36.1% | $1.35B | $1.37B | +0.9% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Jul 29, 2025 | ||||||
| Apr 29, 2025 | ||||||
| Feb 10, 2025 | ||||||
| Oct 29, 2024 | ||||||
| Jul 30, 2024 | ||||||
| Apr 30, 2024 | ||||||
| Feb 13, 2024 | ||||||
| Oct 31, 2023 | ||||||
| Aug 1, 2023 | ||||||
| May 2, 2023 | ||||||
| Feb 7, 2023 | ||||||
| Nov 1, 2022 | ||||||
| Aug 2, 2022 | ||||||
| May 3, 2022 | ||||||
| Feb 8, 2022 | ||||||
| Nov 2, 2021 | ||||||
| Aug 3, 2021 | ||||||
| May 4, 2021 | ||||||
| Feb 9, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 4, 2020 | ||||||
| May 5, 2020 | ||||||
| Feb 13, 2020 | ||||||
| Oct 29, 2019 | ||||||
| Jul 30, 2019 | ||||||
| Apr 30, 2019 | ||||||
| Feb 14, 2019 | ||||||
| Oct 30, 2018 | ||||||
| Jul 31, 2018 | ||||||
| May 1, 2018 | ||||||
| Feb 15, 2018 | ||||||
| Oct 31, 2017 | ||||||
| Aug 1, 2017 | ||||||
| May 4, 2017 | ||||||
| Feb 14, 2017 | ||||||
| Nov 1, 2016 | ||||||
| Aug 9, 2016 | ||||||
| May 9, 2016 | ||||||
| Feb 11, 2016 | ||||||
| Nov 3, 2015 | ||||||
| Aug 4, 2015 | ||||||